Biliary Tract Cancer
Biliary tract cancer or cholangiocarcinoma is one of the types of cancer of the digestive system and is also one of the types of hepatobiliopancreatic tumors (liver, pancreas, and bile ducts).
Biliary tract cancer or cholangiocarcinoma is one of the types of cancer of the digestive system and is also one of the types of hepatobiliopancreatic tumors (liver, pancreas, and bile ducts). It occurs mainly in people over 50 years of age, although it can occur at any age.
Cancer can develop anywhere in the bile duct and, based on its location, is classified into three types:
- Intrahepatic cholangiocarcinoma;
- Perihilar cholangiocarcinoma: Being the most common type of cholangiocarcinoma, accounting for more than half of all cancers of the bile duct;
- Distal cholangiocarcinoma;
Cholangiocarcinoma can also be divided into types, based on the appearance of the cancer cells under the microscope. Over 95% of cancers of the bile duct are carcinomas and the majority are adenocarcinomas.
There are several treatment options for cholangiocarcinoma, including surgery, radiotherapy, locoregional therapies, chemotherapy, targeted therapy, immunotherapy, or palliative therapy.
However, it is essential to get a second opinion for this cancer, as it is uncommon cancer like cholangiocarcinoma, as for any other. A second opinion can provide more information and help you feel more confident about your chosen treatment plan.
Biliary Tract Cancer Studies
Locations
Biliary Cancer Cancer Studies
Details
There are several studies available, here are some of the ones you can find:
| Status | Study | Conditions | Interventions | Locations |
| Recruiting | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | Biliary Tract Cancer | Drug: Nivolumab Drug: DKN-01 |
Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States Dana Farber Cancer Institute Boston, Massachusetts, United States |
| Recruiting | Molecular Profiling of Advanced Biliary Tract Cancers | Biliary Tract Cancer | Other: Tumour and germline molecular profiling |
|
| Recruiting | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | Biliary Tract Cancer |
|
|
| Not yet recruiting | Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer | Biliary Tract Cancer | Drug: Cisplatin Drug: Gemcitabine Drug: Oxaliplatin (and 2 more…) |
|
| Recruiting | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer | Biliary Tract Cancer | Drug: mFOLFOX6, Atezolizumab and Bevacizumab | Universitätsklinikum Essen Essen, NRW, Germany Clínica Universidad de Navarra Pamplona, Spain |
| Not yet recruiting | A Trial of SHR1258 in Patients With Biliary Tract Cancer | Biliary Tract Cancer |
|
|
| Not yet recruiting | A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer | Biliary Tract Cancer | Drug: ZKAB001 5mg/kg Drug: Capecitabine |
|
| Not yet recruiting | Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer | Biliary Tract Cancer | Drug: Gemcitabine/Capecitabine Drug: Capecitabine |
|
| Unknown | Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer | Biliary Tract Cancer |
|
|
| Recruiting | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | Biliary Tract Cancer |
|
|
0-800-777-2331
24/7 EMERGENCY NUMBER
Call us now if you are in a medical emergency need, we will reply swiftly and provide you with a medical aid.